AGP LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 92.86 PKR | +0.53% |
|
+5.00% | +32.07% |
| 04-30 | AGP Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 02-29 | AGP Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2022 | 14.46B 51.99M 4.11B | Sales 2023 | 18.74B 67.4M 5.32B | Capitalization | 19.69B 70.79M 5.59B |
|---|---|---|---|---|---|
| Net income 2022 | 1.57B 5.65M 446M | Net income 2023 | 1.56B 5.63M 445M | EV / Sales 2022 | 1.46 x |
| Net Debt 2022 | 2.96B 10.65M 841M | Net Debt 2023 | 11.6B 41.7M 3.29B | EV / Sales 2023 | 1.67 x |
| P/E ratio 2022 |
11.6
x | P/E ratio 2023 |
12.6
x | Employees | 1,574 |
| Yield 2022 |
3.08% | Yield 2023 |
3.56% | Free-Float | 16.07% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +0.53% | ||
| 1 week | +5.00% | ||
| Current month | +0.53% | ||
| 1 month | +6.61% | ||
| 3 months | +27.99% | ||
| 6 months | +27.55% | ||
| Current year | +32.07% |
1 week
86.51
93.50
1 month
78.3094.10
Current year
60.2197.00
1 year
46.0097.00
3 years
46.00158.99
5 years
46.00158.99
10 years
46.00158.99
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 12-31 | |
Junaid Aslam
DFI | Director of Finance/CFO | - | - |
Shumaila Amir
CTO | Chief Tech/Sci/R&D Officer | - | 28/02/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | 06/06/18 | |
| Chief Executive Officer | - | 12-31 | |
Kamran Nishat
BRD | Director/Board Member | - | 29/11/15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 01/07/24 | 92.86 | +0.53% | 74,135 |
| 28/06/24 | 92.37 | +3.21% | 111,251 |
| 27/06/24 | 89.5 | +1.12% | 71,024 |
| 26/06/24 | 88.51 | +0.35% | 299,864 |
| 25/06/24 | 88.2 | -0.27% | 68,482 |
End-of-day quote Pakistan S.E., July 30, 2024
More quotes
AGP Limited is a Pakistan-based pharmaceutical company. The principal activities of the Company include import, marketing, export, dealership, distribution, wholesale, and manufacturing of all kinds of pharmaceutical products. It owns a range of products catering to distinct therapeutic needs of the market. It offers a diverse portfolio of products in internal medicine, gynecology, pediatrics, nutraceutical, neuropsychiatry, cardiometabolic, hepatology, and orthopedic. Its products include Afdol, Nebcin, Exotan, Nergab, Febuxin, Zerifax, Protege, Maxna, Lucast, Urso, Kefzol, Algocin, Poze, Analar, Magnus MR, Novafol, Vita-NEM Plus, Colidrop, Daplazole, Lipomax, and Rigix, among others. Its subsidiary includes OBS AGP (Private) Limited (OBS AGP). OBS AGP is in the business of trading pharmaceutical products.
Sector
Pharmaceuticals
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +32.07% | 92.93M | |
| +56.86% | 815B | |
| +43.90% | 641B | |
| -6.57% | 352B | |
| +17.32% | 314B | |
| +9.94% | 303B | |
| +16.08% | 242B | |
| +2.29% | 224B | |
| +13.96% | 218B | |
| +7.98% | 168B |
- Stock Market
- Equities
- AGP Stock
